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Summary The identification of biomarkers to complement pathological stage for a more accurate prognosis
and help clinicians decide on treatment is still an open problem for patients with lung cancer. Expression of
P53 protein was detected by an immunohistochemical approach using the monoclonal antibody PAbl8O1 on
paraffin-embedded sections of tumours obtained surgically from 102 stage II-II1a patients with non-small-cell
lung cancer (52 squamous cell carcinomas, 50 adenocarcinomas). [3H]Thymidine labelling index, an indicator of
the S-phase cell fraction, was evaluated on histological sections of [3H]thymidine-labelled tumour samples.
DNA ploidy was defined by flow cytometric analysis on frozen tumour tissue. The biomarkers, histology and
pathological stage were analysed in relation to relapse-free survival in univariate and multivariate analyses.
Stage and interaction between [3H]thymidine labelling index and histology provided significant prognostic
information for the overall series. [3H]thymidine labelling index was an independent prognostic indicator of 3
year relapse-free survival in patients with adenocarcinoma. The results indicate the importance of cell
proliferation to complement prognostic information provided by pathological stage in patients with stage II-
LIIa adenocarcinomas.
Keywords: DNA ploidy; lung cancer; P53 expression; prognosis; [3H]thymidine labelling index
During the last decade lung cancer has become the major
cause of death from cancer in Western countries. The
treatment of choice remains surgery when the disease is
operable. In fact, adjuvant treatments including chemother-
apy and radiotherapy have been extensively used, but no
definitive conclusions have been reached about their
effectiveness (Le Chevalier et al., 1991; Marino et al., 1994).
In particular, combined therapies have not unequivocally
proved to be superior to a single treatment modality, i.e.
surgery in operable locally advanced stages II and i11a
tumours (Martini and Flehinger, 1987; Naruke et al., 1988).
The identification of biological markers to complement
clinicopathological findings for a more accurate definition of
individual patients prognosis and to help clinicians in
treatment decision-making is therefore of utmost impor-
tance. Moreover, it is hoped that, as for some biological
factors in other human tumour types (Paradiso et al., 1993;
Amadori et al., 1994), predictors of response to different
systemic treatments will also be identified in lung cancer.
DNA ploidy, cell proliferation, and products of oncogenes or
tumour-suppressor genes in lung cancer have been extensively
investigated (Volm et al., 1985; Alama et al., 1990; Isobe et
al., 1990; Miyamoto et al., 1991; Silvestrini et al., 1991;
Tungekar et al., 1991; Filderman et al., 1992; McLaren et al.,
1992; Quinlan et al., 1992; M0rkve et al., 1993; Scagliotti et
al., 1993; Ebina et al., 1994; Passlick et al., 1994). However,
consistent results have not been achieved, probably owing to
the heterogeneity in terms of stage and treatment in case
series analysed, which implies interference of confounding
factors.
On a series of patients with operable locally advanced
non-small-cell lung cancer (NSCLC), we analysed the role of
P53 expression, S-phase cell fraction and DNA ploidy, alone
or in association with pathological characteristics, in
providing information on relapse-free survival.
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Materials and methods
Case series
From February 1988 to June 1992, 126 consecutive patients
with operable stage II or IlIa NSCLC underwent surgery at
the Istituto Nazionale Tumori of Milan, Italy. Age, gender,
clinical presentation, preoperative diagnosis, tumour location,
type of treatment and TNM stage according to the
International Staging System (Mountain, 1986) was recorded
for each patient. Preoperative staging included chest radio-
graphy, computerised tomography or magnetic resonance of
the whole body, cytological sputum examination and
bronchofiberoscopy with brushing and biopsy when possi-
ble. Pulmonary scan was performed when a pneumonectomy
was suspected, and pulmonary function tests including
spirometry and blood gas analysis were done in all patients.
In our study, patients had not been previously treated by
surgery or any adjuvant treatment. Biological information,
including P53 expression, cell proliferation and DNA ploidy,
was available for 102 patients. Twelve were pTl N1, 44 pT2
N1, 8 pT3 NO, 5 pT3 NI and 33 pTl-3 N2 cancers. The case
series included 52 squamous cell carcinomas and 50
adenocarcinomas. The surgical procedure was sublobular
resection in three cases, lobectomy in 70 cases and
pneumonectomy in 29 cases. In any case, a mediastinal
lymphadenectomy was performed.
Immediately after surgery, pathological material from
different areas of the tumour was (1) processed for
conventional histological procedures, after previous incuba-
tion with [3H]thymidine, and (2) frozen in liquid nitrogen and
stored at - 80°C for DNA content determination.
Tumour cell proliferation
Tumour fragments were incubated for 1 h with a DNA
precursor, [3Hithymidine, and fixed in formalin. These steps
of the procedure were carried out using a commercial kit
(Ribbon, Milan, Italy). Histological sections (4 gm) were
processed for autoradiography (Silvestrini et al., 1991).Tumour cells were scored as labelled when they showed more
than six nuclear grains over a clear background, and the
[3H]thymidine labelling index ([3H]dT LI) was determined by
scoring 3000-5000 total cells from different areas of each
tumour. The evaluation was performed independently by two
observers who were unaware of the clinical course.
P53 protein expression
Sections (4 ,um), consecutive to those used for [3H]dT LI
determination, were submitted to the immunohistochemical
detection of P53 protein by using PAbl801 (Oncogene
Science, Manhasset, NY, USA). Sections were incubated
with PAbl801 (2 ,ug ml-') for 1 h at room temperature and
successively with a goat anti-mouse immunoglobulin diluted
1: 200 (30 min) and then treated with an avidin-biotin
peroxidase system (Vectastain ABC Kit, Vector Laboratories,
Burlingame, CA, USA). The antigen-antibody complex was
visualised using diaminobenzidine (DAB) and hydrogen
peroxidase chromogen substrate (5 min) and then counter-
stained with thionine. A lung carcinoma with a high P53
protein expression was used as positive control; negative
controls were obtained by omission of the primary
monoclonal antibody.
The slides were examined with an automated image system
(Discovery, Becton Dickinson, Leiden, The Netherlands).
Thionine-stained nuclei were identified on the slides using a
620 nm filter, and DAB-positive nuclei were detected using a
500 nm filter. Thionine was used because its absorption
spectrum does not interfere with the DAB spectrum. The
image was segmented into objects and background by
interactive thresholding. Objects that were too small
(artefacts) or too large (overlapping nuclei) were removed
from the counting on the basis of several morphological
features, including nuclear area, perimeter, skeleton size and
densitometric features. Negative controls were used to
establish non-specific background levels, and the positive
antibody threshold was defined on the control slide. The
measurement was performed on about 5000 total nuclei from
different areas for each tumour.
DNA ploidy
Nuclei suspensions were prepared from frozen material as
described previously (Costa et al., 1992). The suspensions
were stained with a solution containing propidium iodide
(50 Mg ml-'), RNAase, (100 kU ml-') and Nonidet P40
(0.05%) for at least 20 min at 4°C. Human normal
lymphocytes were used as an internal standard. DNA
content was measured with a FACScan flow cytometer
(Becton Dickinson, San Jose, CA, USA), and a total of
30 000 nuclei was acquired for each sample. DNA ploidy was
expressed as DNA index (DI), and the samples were defined
'diploid' when the DI was 1.0, 'aneuploid' when two distinct
peaks could be discerned (indicating the presence of an
abnormal DNA cell population), or 'multiploid' when more
than one abnormal stemline was present.
Statistical analysis
The free-distribution Kolmogorov-Smirnov test was used to
compare the distributions of P53 expression and [3H]dT LI
values between DNA ploidy subsets, as well as between stage
and histology groups. The relationship between P53
expression and [3H]dT LI values was assessed by Spearman's
correlation coefficient, and the association between P53
expression and DNA ploidy, as well as between such
biomarkers and pathological characteristics was investigated
by the logistic regression model. In this model, each
regression coefficient is the logarithm of an odds ratio, and
under the null hypothesis of no association, the odds ratio is
expected to be 1.00.
Relapse-free survival was computed starting from the date
of surgery, and the median follow-up was 20 months (range,
1-71 months). New disease manifestation (local recurrence
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or distant metastasis) occurred in 57 of the 102 patients. The
prognostic role of the variables was evaluated by a Cox
regression model in univariate and in multivariate analyses.
Hazard ratios and their 95% confidence limits (CL) were
determined by using as a reference the putative best
prognostic category. Stage, histology, P53 expression and
DNA ploidy were used as categorical variables, whereas
[3H]dT LI was used as a continuous variable. The use of a
continuous variable X (in its original measurement scale) in a
Cox regression model imposes a log-linear relationship
between the hazard ratio and X. The assumption of log-
linearity was investigated following the approach suggested
by Andersen et al. (1992). This approach consists of fitting a
regression model containing the continuous variable X and
some dummy variables built using predetermined cut-off
points of X (i.e. tertiles). If the inclusion of the dummy
variables does not significantly improve the fit of the model,
the assumption of log-linearity appears to be tenable. In the
multivariate analysis, all the variables and their clinically
Table I Relationship between DNA ploidy and P53 expression and
S-phase cell fraction
P53+ [3H]dT LI (%)
(%) (median value)
Diploid 58 6.9
(0.2-41.7)a
Aneuploid 54 6.5
(O.2-44.3)a
P-value 0.86 0.86c
aIn parenthesis, range. bLogistic regression model. cKolmogorov-
Smirnov test.
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Figure 1 S-phase cell fraction as a function of histological type
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relevant first-degree interactions were considered, and the
final model was obtained by means of a backward selection
procedure.
Results
P53 protein accumulation was nuclear and was observed in 56
(55%) of the 102 tumours. P53-expressing tumours showed a
median of 21% positive cells, with a range of 0.2-63%. The
median [3H]dT LI value was 6.5%, with a range of 0.01 -
44.3%. Twelve tumours showed only a diploid population,
and 90 tumours (88%) an aneuploid DNA population.
Among these, 14 cases exhibited multiploid cell populations.
P53 expression and S-phase cell fraction were not significantly
related (r.=0.13, P=0.18). Moreover, the frequency of p53-
positive tumours and the median [3H]dT LI values were
similar in diploid and aneuploid tumours (Table I).
P53 expression and DNA ploidy were not related to
pathological stage or histology (data not shown). Conversely,
cell proliferation was not related to stage, but it was
significantly associated with tumour histology (K=3.27,
P= 0.0001). In fact, a lower median [3H]dT LI (3.2%) was
observed in adenocarcinomas than in squamous cell
carcinomas (13.6%), even though the ranges partly over-
lapped. This finding applies also to stage II and stage lIla,
distinctly analysed (Figure 1).
When the biological and pathological variables were singly
considered for the overall series, the only significant indicator
of relapse-free survival during the observation period was
pathological stage (Table II). In fact, the hazard ratio
between stage I11a and stage II patients was 2.11
(P=0.0053), with a median time to relapse of 8.5 and 36
months respectively. With regard to the biological markers, a
different risk (although not statistically significant) was
observed in relation to DNA ploidy, with a hazard ratio of
Table II Univariate analysis of relapse-free survival in 102 patients
Hazard ratio
Variable (95% CL) X2a p
Stage
MIla vs 2.11 7.79 0.0053
(1.25-3.55)
Histology
Adenocarcinoma vs squamous cell carcinomab 1.17 0.36 0.55
(0.70-1.97)
DNA ploidy
Aneuploid vs diploidb 1.28 0.56 0.45
(0.68-2.41)
Multiploid vs diploidb 1.48 0.80 0.37
(0.63-3.45)
P53 expression
Positive vs negativeb 1.0 0.05 0.82
(0.56-1.58)
[3H]dT LI
Continous variable 1.0 <0.01 0.97
(0.97-1.03)
aComputed by the Wald statistic. bReference category.
Table III Multiple regression analysis of relapse-free survival
Hazard ratio
Variable (95% CL) X2a p
Initial model
Stage, MIla vs Ilb 3.38 7.98 0.005
(1.45-7.85)
Histology, adenocarcinoma vs 1.34 0.76 0.38
squamous cell carcinomab (0.26-1.67)
DNA ploidy, aneuploid vs 1.09 0.07 0.79
diploidb (0.56-2.11)
DNA ploidy, multiploid vs 1.34 0.42 0.52
diploidb (0.56-3.28)
P53, positive vs negativeb 1.0 0.16 0.69
(0.51-1.56)
[3H]dT LI, continuous variable 1.0 0.03 0.87
(0.96-1.06)
[3H]dT LI and stage (interaction) 1.0 1.39 0.24
(0.9-1.03)
[3H]dT LI and histology (interaction) 1.09 4.37 0.037
(1.0-1.17)
Final model
Stage, IIIa vs Ilb 2.33 9.53 0.002
(1.44-7.75)
Histology, adenocarcinoma vs 1.38 0.50 0.48
squamous cell carcinomab (0.57-3.36)
[3H]dT LI, continuous variable 0.99 0.34 0.56
(0.97-1.06)
[3H]dT LI and histology (interaction) 1.09 4.55 0.033
(1.01-1.17)
aComputed by the Wald statistic. bReference category.1.48 for patients with multiploid compared with patients with
diploid tumours. Conversely, no prognostic indication was
observed for P53 expression or for cell proliferation, which
was used as a continuous variable.
We investigated the joint prognostic effect of stage,
histology, DNA ploidy, P53 expression and [3H]dT LI on
relapse-free survival (Table III) by initially inserting in the
regression model all variables and the relevant first-degree
interactions (i.e. [3H]dT LI by histology, and [3H]dT LI by
stage). Stage and the interaction between [3H]dT LI and
histology provided significant prognostic information (P<
0.05). The final model, including only stage, histology, [3H]dT
LI and the first-degree interaction between histology and
[3H]dT LI, indicated that only stage and the interaction
between cell proliferation marker and histology were
significantly associated with relapse-free survival.
The predicted probabilities of 3 year relapse-free survival
obtained by the final model as a function of [3H]dT LI, stage
and histology are shown in Figure 2. [3H]dT LI showed a
significant prognostic relevance in patients with adenocarci-
noma (HR= 1.07, 95% CL= 1.01- 1.44; P=0.027) but not in
patients with squamous cell carcinoma (HR=0.99; P=0.56).
In fact, for both histologies the prognosis of stage IIa
patients was worse than that of stage II patients. However, in
adenocarcinoma patients, a statistically significant inverse
relation was also observed between relapse-free survival
probability and [3H]dT LI values within each pathological
stage. Conversely, in squamous cell carcinoma patients, the
prognosis was not influenced by cell proliferation.
For clinical purposes, the most prognostic discriminant
[3H]dT LI cut-off was investigated in adenocarcinoma (Figure
3). The values of 4% and 3% respectively for stage II and
Ila identified two subgroups of patients at different risk of
relapse within each stage, with the maximum discriminant
power in stage MIIa (rapidly vs slowly proliferating tumours:
HR= 8.2, 95% CL =2.8-24.1; P=0.0001).
Discussion
Our results showed that P53 expression, DNA ploidy and
[3H]dT LI were unrelated biological variables in locally
advanced operable squamous cell and adenocarcinomas of
100
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the lung. In particular, the independence of P53 expression
and cell proliferation, as observed for other tumour types
(Silvestrini et al., 1993; Costa et al., 1995), supports the
hypothesis that P53 has other biological functions in addition
to cell-cycle regulation. Moreover, except for a relation
between cell proliferation and histology, such biological
variables were independent of pathological characteristics,
in agreement with previous data (Kerr et al., 1983; Alama et
al., 1990; Isobe et al., 1990; Miyamoto et al., 1991; Silvestrini
et al., 1991; Filderman et al., 1992; Quinlan et al., 1992;
M0rkve et al., 1993; Scagliotti et al., 1993; Ebina et al., 1994;
Passlick et al., 1994).
P53 expression of human lung cancer has been determined
immunohistochemically on frozen (McLaren et al., 1992;
Passlick et al., 1994) or routinely processed paraffin-
embedded sections (Quinlan et al., 1992; Ebina et al.,
1994). McLaren et al. (1992) showed no correlation between
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P53 expression, detected by different monoclonal antibodies
on frozen sections, and prognosis of patients with squamous
cell and adenocarcinomas ofthe lung. More recently, Passlick
et al. (1994) showed that P53 immunostaining by PAb 1801
of frozen sections from NSCLC predicts a poor clinical
outcome only in early stages. In contrast, Quinlan et al.
(1992), on paraffin-embedded tissue, indicated a strong
correlation between p53 expression and poor survival for
NSCLC patients. This held true for stages I and II squamous
cell carcinomas and adenocarcinomas in univariate analysis,
but the authors were unable to verify the independent role of
the biomarker by multivariate analysis. Ebina et al. (1994)
showed that P53 expression detected on paraffin-embedded
tissue was an independent predictor of a short survival in a
subset of curable patients with P53 negative- or more than
10% P53-positive tumour cells.
Such conflicting results can be ascribed to heterogeneity in
methodological approaches and case series. In particular,
artefacts could be due to a long-term fixation (Silvestrini et
al., 1995) and fixation gradient, or to uneven distribution of
the antibodies. Moreover, criteria for patient inclusion were
not reported in some studies, and selected series were
probably analysed. Our results in a consecutive series of
patients failed to evidence a prognostic role ofP53 expression
in operable, locally advanced NSCLC.
Several studies have attempted to define the prognostic
role of DNA ploidy in patients with all NSCLC histologies
and at all stages (Volm et al., 1985; Isobe et al., 1990;
Miyamoto et al., 1991; Filderman et al., 1992; M0rkve et al.,
1993). Most studies have shown a worse prognosis for
patients with aneuploid than for those with diploid tumours
(Volm et al., 1985; Isobe et al., 1990; Miyamoto et al., 1991;
Filderman et al., 1992), but contrasting results are not
lacking (Cibas et al., 1989; M0rkve et al., 1993). In the
present study, DNA abnormalities were observed in a very
high percentage of tumours (about 90%), and the prognosis
was slightly worse for patients with mutliploid tumours than
for those with diploid tumours, even though the difference
was not statistically significant.
The rate of tumour cell proliferation has proved to be a
prognostic factor in several tumour types (Silvestrini, 1994).
In particular, [3H]dT LI, an indicator of the fraction of cells
actively synthesising DNA, has been demonstrated to be a
predictor of prognosis in stage I NSCLC (Alama et al., 1990;
Silvestrini et al., 1991). In the present study on stage II-IIIa
NSCLC, we showed that [3H]dT LI has an additive
prognostic role in adenocarcinomas but not in squamous
cell carcinomas. Such a finding suggests that in patients with
a favourable histology and operable, locally advanced disease
the biological variables give no prognostic information.
In conclusion, analysis of the clinical relevance of some
biological factors in advanced lung cancer has shown that
multiclonality is a weak indicator ofrisk, whereas the S-phase
cell fraction provides independent information additive to
that given by stage, which remains the most important factor
in squamous cell carcinoma. The failure of P53 expression to
give prognostic information could indicate that the marker
plays a role in the initiation of tumour malignancy but is of
minor importance in tumour progression.
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